{"filing":{"accession_number":"0001104659-26-072408","cik":"0001425205","ticker":"IOVA","company_name":"IOVANCE BIOTHERAPEUTICS, INC.","form":"8-K","filing_date":"2026-06-10","report_date":null,"primary_document":"tm2613648d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1425205/000110465926072408/tm2613648d1_8k.htm"},"events":[{"id":5611,"run_id":4920,"accession_number":"0001104659-26-072408","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Iovance held its Annual Meeting of Stockholders on June 10, 2026, with certified voting results on seven proposals including director elections, executive compensation advisory votes, auditor ratification, equity plan amendments, and a certificate of incorporation amendment to increase authorized shares. All proposals passed.","company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","filing_date":"2026-06-10","form":"8-K","submitted_at":null,"items":[{"id":5967,"accession_number":"0001104659-26-072408","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the certified results of Iovance's Annual Meeting of Stockholders held on June 10, 2026, including voting outcomes on seven proposals: director elections, executive compensation advisory votes, auditor ratification, equity plan amendments, and a certificate of incorporation amendment to increase authorized shares. The disclosure includes vote counts (for, against, abstain, broker non-votes) for each proposal, all of which passed. This is a textbook shareholder_vote_results event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T21:02:54.880479+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":5612,"run_id":4920,"accession_number":"0001104659-26-072408","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"Iovance received marketing authorization from Australia's Therapeutic Goods Administration for Amtagvi® in advanced melanoma on June 4, 2026. This regulatory approval is material to the company's commercial prospects and pipeline.","company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","filing_date":"2026-06-10","form":"8-K","submitted_at":null,"items":[{"id":5968,"accession_number":"0001104659-26-072408","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The Company received marketing authorization from Australia's Therapeutic Goods Administration for Amtagvi® in advanced melanoma on June 4, 2026. This is a material regulatory approval event for a biopharmaceutical company's marketed product, but it does not fit neatly into the standard 8-K taxonomy (no dedicated Item for product approvals). The approval would affect investor assessment of the company's commercial prospects and pipeline, warranting classification as other_material rather than forcing it into an ill-fitting category.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T21:02:54.880479+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5967,"accession_number":"0001104659-26-072408","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the certified results of Iovance's Annual Meeting of Stockholders held on June 10, 2026, including voting outcomes on seven proposals: director elections, executive compensation advisory votes, auditor ratification, equity plan amendments, and a certificate of incorporation amendment to increase authorized shares. The disclosure includes vote counts (for, against, abstain, broker non-votes) for each proposal, all of which passed. This is a textbook shareholder_vote_results event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T21:02:54.880479+00:00","company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","filing_date":"2026-06-10"},{"id":5968,"accession_number":"0001104659-26-072408","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The Company received marketing authorization from Australia's Therapeutic Goods Administration for Amtagvi® in advanced melanoma on June 4, 2026. This is a material regulatory approval event for a biopharmaceutical company's marketed product, but it does not fit neatly into the standard 8-K taxonomy (no dedicated Item for product approvals). The approval would affect investor assessment of the company's commercial prospects and pipeline, warranting classification as other_material rather than forcing it into an ill-fitting category.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T21:02:54.880479+00:00","company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","filing_date":"2026-06-10"}]}